Using cells from an unrelated donor

Mesoblast and its United States-based sister company, Angioblast Systems Inc., have commenced Phase 2 clinical trials in the United States examining the safety and efficacy of allogeneic (derived from universal donors and used in unrelated recipients) Mesenchymal Precursor Cells.

Both companies intend to commercialise 'off-the-shelf' products available for immediate use where speed is critical, such as for patients with compound fractures or heart attacks.

Off-the-shelf products have the commercial advantages of reducing the cost of goods sold as a result of economies of scale and present an attractive option for partnering with international pharmaceutical companies.


Product Development




 
Last Share Price

January 06 - Mesoblast Named 2009 North American Emerging Company By Frost And Sullivan

November 27 - Executive Director's Presentation at the AGM

November 27 - Chairman's speech to AGM

November 24 - Investor Briefing – The CEO Transcript

May 2008 - Issue Nine

September 2007 - Issue Eight

March 2007 - Issue Seven

August 2006 - Issue Six

 

 

© Copyright Mesoblast Limited 2006. All rights reserved.
Website design by Infoprobe Australia

disclaimer | privacy policy

home | contact | sitemap | Angioblast Systems | webmail
the company | the technology | product development | investor centre | news room